MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

32.19 -4.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.98

Máximo

32.47

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+69.04% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

472M

2.1B

Abertura anterior

36.24

Fecho anterior

32.19

Sentimento de Notícias

By Acuity

100%

0%

330 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de abr. de 2026, 23:44 UTC

Conversa de Mercado
Notícias Principais

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12 de abr. de 2026, 23:38 UTC

Conversa de Mercado
Notícias Principais

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12 de abr. de 2026, 23:38 UTC

Conversa de Mercado

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12 de abr. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12 de abr. de 2026, 23:31 UTC

Conversa de Mercado

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12 de abr. de 2026, 23:09 UTC

Conversa de Mercado
Notícias Principais

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12 de abr. de 2026, 23:06 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de abr. de 2026, 23:06 UTC

Conversa de Mercado

Australian Dollar Ripe for a Downward Correction -- Market Talk

12 de abr. de 2026, 22:56 UTC

Notícias Principais

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12 de abr. de 2026, 22:54 UTC

Notícias Principais

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12 de abr. de 2026, 22:53 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12 de abr. de 2026, 22:51 UTC

Notícias Principais

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12 de abr. de 2026, 22:50 UTC

Conversa de Mercado
Notícias Principais

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12 de abr. de 2026, 22:37 UTC

Conversa de Mercado
Notícias Principais

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

11 de abr. de 2026, 00:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Big Yachts, Big Bucks -- Barrons.com

10 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 de abr. de 2026, 21:01 UTC

Ganhos

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 20:31 UTC

Conversa de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 de abr. de 2026, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 de abr. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

69.04% parte superior

Previsão para 12 meses

Média 54.5 USD  69.04%

Máximo 90 USD

Mínimo 24 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

9

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat